Ubs Asset Management Americas Inc Altimmune, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 79,266 shares of ALT stock, worth $553,276. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,266
Previous 105,182
24.64%
Holding current value
$553,276
Previous $699,000
30.47%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ALT
# of Institutions
189Shares Held
39.4MCall Options Held
913KPut Options Held
743K-
Black Rock Inc. New York, NY5.32MShares$37.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$34.8 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$27.1 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$23.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$19.2 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $342M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...